Detalles de la búsqueda
1.
Clinical targeting of HIV capsid protein with a long-acting small molecule.
Nature
; 584(7822): 614-618, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32612233
2.
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
N Engl J Med
; 386(19): 1793-1803, 2022 05 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35544387
3.
Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus.
Value Health
; 26(6): 810-822, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36566886
4.
Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.
J Infect Dis
; 226(11): 1985-1991, 2022 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36082606
5.
Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.
HIV Clin Trials
; 15(6): 269-73, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25433666
6.
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
J Infect Dis
; 208(1): 32-9, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23532097
7.
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
Lancet HIV
; 10(8): e497-e505, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37451297
8.
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Lancet HIV
; 10(1): e15-e23, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36566079
9.
Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
Curr Opin HIV AIDS
; 17(1): 15-21, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34871187
10.
Risk factors for proteinuria in HIV-infected and -uninfected Hispanic drug users.
Am J Kidney Dis
; 52(4): 683-90, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18572293
11.
Pharmacologic consideration for the use of antiretroviral agents in the elderly.
J Clin Pharmacol
; 48(10): 1212-25, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18812611
12.
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Lancet HIV
; 5(4): e162-e171, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29475804
13.
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
HIV Clin Trials
; 18(3): 135-140, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28303753
14.
Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial.
Lancet Child Adolesc Health
; 1(1): 27-34, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30169223
15.
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.
J Acquir Immune Defic Syndr
; 75(2): 226-231, 2017 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28272164
16.
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Lancet HIV
; 3(12): e561-e568, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27765666
17.
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Lancet HIV
; 3(4): e158-65, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27036991
18.
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
Antivir Ther
; 20(3): 317-27, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25321623
19.
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
J Acquir Immune Defic Syndr
; 68(3): 310-3, 2015 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25469527
20.
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Pediatr Infect Dis J
; 34(4): 376-82, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25760565